Seroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a university hospital in Turkey

Basit Öğe Kaydı
dc.contributor.authorSit, Dede
dc.contributor.authorKadiroglu, Ali Kemal
dc.contributor.authorKayabasi, Hasan
dc.contributor.authorYilmaz, M. Emin
dc.contributor.authorGoral, Vedat
dc.date.accessioned2024-04-24T17:14:27Z
dc.date.available2024-04-24T17:14:27Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Hepatitis B (HBV) and C (HCV) viruses are the most common viruses that cause viral infections among the hemodialysis patients. Objectives: To assess the prevalence of HBV and HCV in predialytic chronic kidney disease (CKD) patients. Design: A cross-sectional study. Subjects: 171 consecutive predialytic CKD patients. Measurements: Third-generation micro-ELISA assay was used for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core (anti-HBc) and surface antibody (anti-HBs), secretory form of hepatitis B envelop antigen (HBeAg), antibody to secretory form of hepatitis B envelop antigen (anti-HBe), and ELISA for antibody to hepatitis C virus (anti-HCV). Results: The main causes of CKD were 29.8% diabetic nephropathy, 19.9% chronic glomerulonephritis, 16.3% hypertensive nephrosclerosis, 14.0% unknown, 5.3% amyloidosis, 4.7% autosomal-dominant polycystic kidney disease, 4.1% chronic tubuluointerstitial nephritis, 3.5% malignancies, 1.7% benign prostatic hypertrophy, 0.6% Alport syndrome. The seroprevalence of hepatitis was: HBsAg 10.5%, anti-HBc 36.8%, anti-HBs 28.7%, HBeAg 5.3%, anti-HBe 32.7%, anti-HCV 7% and HBsAg+ anti-HCV 0.6%. Conclusions: The seroprevalence of HBsAg and anti-HCV among predialytic CKD patients was similar to our patients in hemodialysis program. Copyright (c) 2007 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000098239
dc.identifier.endpage137en_US
dc.identifier.issn0300-5526
dc.identifier.issn1423-0100
dc.identifier.issue2en_US
dc.identifier.pmid17191015
dc.identifier.scopus2-s2.0-33846963163
dc.identifier.scopusqualityQ2
dc.identifier.startpage133en_US
dc.identifier.urihttps://doi.org/10.1159/000098239
dc.identifier.urihttps://hdl.handle.net/11468/17952
dc.identifier.volume50en_US
dc.identifier.wosWOS:000243564200010
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofIntervirology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Kidney Diseaseen_US
dc.subjectHepatitis B Surface Antigenen_US
dc.subjectAnti-Hepatitis C Virusen_US
dc.titleSeroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a university hospital in Turkeyen_US
dc.titleSeroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a university hospital in Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu